Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Tetra, are a quadrivalent influenza vaccine presented as a vaccine for intramuscular use. It is used to prevent seasonal influenza infection in individuals at risk, including children, adults and the elderly. GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is a quadrivalent influenza vaccine indicated for the prevention of influenza caused by the included virus strains. - Seasonal influenza: reduces the risk of infection from the four vaccine‑matched influenza viruses. - Influenza B infection: provides specific protection against B/Phuket/3073/2013 and B/Austria/1359417/202 strains. - High‑risk populations: helps lower the incidence of severe disease in elderly persons, young children, and individuals with chronic health conditions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema at the site. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache: mild headache occurring shortly after vaccination. - Myalgia: temporary muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may follow vaccination. - Seizures: infrequent occurrence, especially in children with a history of febrile seizures. - Severe allergic reaction: angioedema or bronchospasm. - Thrombocytopenia: rare drop in platelet count.

Influvac Tetra should be administered only after evaluating the following considerations. - Allergy to vaccine components: avoid if the patient has a known severe allergy to any ingredient. - History of severe allergic reaction to previous influenza vaccines: defer administration. - Acute febrile illness: postpone vaccination until recovery. - Egg allergy: assess risk; vaccine may contain trace egg protein. - Immunocompromised status: monitor response, as efficacy may be reduced. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that affect immune response. Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration to prevent interference. - Immunoglobulin or blood products given within 3 days: may neutralize vaccine antigens.

Moderate Interactions (Monitor Closely): - Antiviral medications (e.g., oseltamivir): may slightly reduce immunogenicity. - Immunosuppressive therapy: monitor antibody response, may need revaccination. - Corticosteroids at high dose: possible diminished vaccine efficacy.